ES2462921T3 - Sales de lercanidipino - Google Patents

Sales de lercanidipino Download PDF

Info

Publication number
ES2462921T3
ES2462921T3 ES05776228.8T ES05776228T ES2462921T3 ES 2462921 T3 ES2462921 T3 ES 2462921T3 ES 05776228 T ES05776228 T ES 05776228T ES 2462921 T3 ES2462921 T3 ES 2462921T3
Authority
ES
Spain
Prior art keywords
lercanidipine
crystalline
salt
besylate
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05776228.8T
Other languages
English (en)
Spanish (es)
Inventor
Amedeo Leonardi
Gianni Motta
Markus Von Raumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Recordati Ireland Ltd
Recordati Industria Chimica e Farmaceutica SpA
Original Assignee
Recordati SA
Recordati Ireland Ltd
Recordati Industria Chimica e Farmaceutica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA, Recordati Ireland Ltd, Recordati Industria Chimica e Farmaceutica SpA filed Critical Recordati SA
Application granted granted Critical
Publication of ES2462921T3 publication Critical patent/ES2462921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES05776228.8T 2004-08-24 2005-08-22 Sales de lercanidipino Expired - Lifetime ES2462921T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
US604149P 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (1)

Publication Number Publication Date
ES2462921T3 true ES2462921T3 (es) 2014-05-26

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05776228.8T Expired - Lifetime ES2462921T3 (es) 2004-08-24 2005-08-22 Sales de lercanidipino

Country Status (19)

Country Link
US (1) US7683179B2 (enExample)
EP (1) EP1799644B1 (enExample)
JP (1) JP2008510754A (enExample)
KR (1) KR20070045351A (enExample)
CN (1) CN101048379A (enExample)
AR (1) AR050467A1 (enExample)
AU (1) AU2005276619B2 (enExample)
BR (1) BRPI0514606A (enExample)
CA (1) CA2575078A1 (enExample)
EA (1) EA011773B1 (enExample)
ES (1) ES2462921T3 (enExample)
IL (1) IL180905A0 (enExample)
MX (1) MX2007002141A (enExample)
NO (1) NO20071515L (enExample)
NZ (1) NZ553127A (enExample)
PE (1) PE20060629A1 (enExample)
TW (1) TW200613275A (enExample)
WO (1) WO2006021397A1 (enExample)
ZA (1) ZA200702364B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR20090026282A (ko) 2006-06-12 2009-03-12 노파르티스 아게 Ｎ-히드록시-３-[４-[[[２-(２-메틸-1ｈ-인돌-３-일)에틸]아미노]메틸]페닐]-2ｅ-２-프로펜아미드의 염을 제조하는 방법
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2049465A2 (en) * 2007-03-14 2009-04-22 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
US8063250B2 (en) 2007-11-26 2011-11-22 Teva Pharmaceutical Industries, Ltd. Crystal forms of O-desmethylvenlafaxine fumarate
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2320739B1 (en) * 2008-08-01 2019-11-27 Chiesi Farmaceutici S.p.A. Pharmaceutical compositions and methods for stabilizing the same
EP2320740B1 (en) * 2008-08-01 2014-03-26 The Medicines Company Pharmaceutical compositions of clevidipine and methods for producing low impurity concentrations of the same
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US8569371B2 (en) * 2010-03-29 2013-10-29 Pliva Hrvatska D.O.O. Crystal forms of O-desmethylvenlafaxine fumarate
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2023219106A1 (ja) * 2022-05-10 2023-11-16 Ｍｙｒｏｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 ２－メチル－２－チアゾリンの塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
WO2004035051A1 (en) * 2002-10-16 2004-04-29 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
EA200700492A1 (ru) 2007-08-31
NZ553127A (en) 2009-07-31
EP1799644B1 (en) 2014-02-12
JP2008510754A (ja) 2008-04-10
ZA200702364B (en) 2008-09-25
PE20060629A1 (es) 2006-08-11
EA011773B1 (ru) 2009-06-30
MX2007002141A (es) 2007-04-27
CN101048379A (zh) 2007-10-03
NO20071515L (no) 2007-05-22
KR20070045351A (ko) 2007-05-02
AU2005276619A1 (en) 2006-03-02
AU2005276619B2 (en) 2009-04-30
AR050467A1 (es) 2006-10-25
BRPI0514606A (pt) 2008-06-17
EP1799644A1 (en) 2007-06-27
US7683179B2 (en) 2010-03-23
CA2575078A1 (en) 2006-03-02
WO2006021397A8 (en) 2006-04-27
WO2006021397A1 (en) 2006-03-02
TW200613275A (en) 2006-05-01
IL180905A0 (en) 2007-07-04
US20060047125A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
ES2462921T3 (es) Sales de lercanidipino
ES2334678T3 (es) Nueva foprma cristalina de hidrocloruro de lercanidipino y procedimiento para su preparacion.
US6852737B2 (en) Crude and crystalline forms of lercanidipine hydrochloride
US12172960B2 (en) Organic compound salts
AU2002327924A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
CN100494175C (zh) 盐酸乐卡地平的溶剂合物和盐酸乐卡地平的晶形
RU2146672C1 (ru) Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
CA2399459C (en) Novel crude and crystalline forms of lercanidipine hydrochloride
HK40105022B (en) Crystalline hydrobromide salt of 5-meo-dmt
HK40105022A (en) Crystalline hydrobromide salt of 5-meo-dmt
CA2380202A1 (en) Novel crude and crystalline forms of lercanidipine hydrochloride
HK1140487B (en) Pharmaceutical compositions containing crystalline form (i) of lercanidipine hydrochloride
KR20130033243A (ko) 아데포비어 디피복실의 공결정
HK1067123B (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and processes for their preparation